Potential of soluble immune checkpoints as prognostic and predictive biomarkers in endometrial cancer

Read full text Summarise with VIRAT
Authors: Boštjan Pirš, Maja Pušić Novak, Luka Roškar, Tea Lanišnik Rižner, Špela Smrkolj
Cited by: 0
References: 7

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Soluble immune checkpoints (sICs) have recently been studied as diagnostic, prognostic and predictive biomarkers in a range of cancers.Aim of presented study was to discover potential diagnostic, prognostic and predictive biomarkers among a set of sICs in endometrial cancer (EC).We included 50 patients diagnosed with EC prior to surgery and 26 women undergoing surgery for benign gynaecologic conditions as controls.We measured plasma concentrations of 16 sICs using Luminex XMAP Multiplex immunosorbent assay, 8 inhibitory (sPD-1, sPD-L1, sPD-L2, sCTLA-4, sLAG3, sTIM3, sBTLA, sHVEM), 6 stimulatory (sICOS, sGITR, sGITR-L, sCD40, sCD27, sCD2) and 2 with mixed role (sCD80, sCD86).Study cohort included 66% of EC patients who had non-aggressive histological type, while 33% of tumors exhibited MMR d eficiency and 14% had aberrant p53 expression.Majority of tumors were confined to the uterus, with 16% of patients having stage cancer of stage IIIA or higher.sICs levels did not significantly differ between control patients and EC patients.Also, sICs levels did not significantly differ by aggressiveness of histological type.Levels of sTIM3 tended to be higher in more advanced stage cancers, similarly, its levels were higher in higher risk group patients.Levels of sPD-1, sPD-L1, sLAG-3, sICOS, sGITR, sGITRL, sCD86 were higher in MMR deficient tumors.Contrary to published findings in a small cohort of EC patients and in other malignancies, we did not detect differing sICs levels in EC patients against patients without cancer.This may be due to majority of the patients in presented study having localised disease.Further studies are needed before ruling out sICs as diagnostic biomarkers in endometrial cancerEC.Biological foundation of higher levels of some sICs in MMR deficient tumors may be their immunoreactivity, stimulating immune response.This finding may be clinically significant, as blood-based prognostic and predictive biomarkers could preclude the need for repeat biopsies and overcome tissue biomarker limitations.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Endometrial and Cervical Cancer Treatments Reproductive System and Pregnancy

Publication details

Journal / source
DiRROS repository (University of Maribor)
Publication date
18 March 2026
Language
EN